EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34257550/
The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • In the current study, researchers aimed to show the presence of EGFR or KRAS mutations in non-tumoral lung cells in patients with adenocarcinoma and negative mutational status. • Via Show More
The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34268392/
1 Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. 2 Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China. 3 Department of Medicine...
The Research Progress of Direct KRAS G12C Mutation Inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34257597/
KRAS mutations have long been considered undruggable. However, a series of direct KRAS mutation inhibitors have been developed since the switch II pocket was discovered recently. This review will summarize...
RAS Nanoclusters Selectively Sort Distinct Lipid Headgroups and Acyl Chains - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34222339/
RAS proteins are lipid-anchored small GTPases that switch between the GTP-bound active and GDP-bound inactive states. RAS isoforms, including HRAS, NRAS and splice variants KRAS4A and KRAS4B, are some of...
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • In this review, authors described how RAS proteins localize to and distribute on the plasma membrane in an attempt to elucidate RAS biology and contribute to the development Show More
Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34217914/
doi: 10.1016/j.canep.2021.101976. Online ahead of print. 1 EpidStrategies, Rockville, MD, USA. Electronic address: [email protected]. 2 Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. Electronic address: [email protected]. 3 AstraZeneca, Gaithersburg,...
-
KRAS Oncogene Connect5yrKey Points • Conclusion/Relevance: “No association was observed between PD-L1 TC ≥ 25 % and OS in any therapy line. PD-L1 IC ≥ 25 % may confer survival benefit among some patients who reach second-line therapy Show More